Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study

ConditionsMetabolic Dysfunction-associated Fatty Liver Disease Hepatic Steatosis Liver Fibrosis

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-90

SponsorChongqing Medical University

About this trial

The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic dysfunction-associated fatty liver disease (MAFLD).

The main question\[s\] it aims to answer are:

\[question 1\] Can hsCAR serve as a clinical indicator to determine whether a patient has MAFD? \[question 2\] Can hsCAR determine whether MAFLD patients are complicated with liver fibrosis?

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Total participants from NHANES 2017-2020

Participants diagnosed with MAFLD. Metabolic dysfunction-associated fatty liver disease (MAFLD) is the term used to describe hepatic steatosis in the presence of metabolic abnormalities, excess weight, obesity, or type 2 diabetic mellitus.

Diagnosis of diabetes mellitus: (1) taking glucose-lowering drugs; (2) HbA1c ≥ 6.5% (48 mmol/mol); (3) fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL); (4) 2-hour plasma glucose (2hPG) ≥ 11.1 mmol/L (200 mg/dL).

Overweight or obesity: defined as BMI≥25 kg/m2 in Caucasians or BMI≥23 kg/m2 in Asians

Disqualifiers

Liver ultrasound data not available

participants without complete clinical data

participants under 18 years old

participants with cancer.

Trial population

They all come from the National Health and Nutrition Examination Survey, which is a database that contains information about demographics, dietary, examination, laboratory and questionnaire of the American population obtained through sophisticated sampling strategies.

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

high-sensitivity C-reactive protein to albumin ratio
Other intervention
High-sensitivity C-reactive protein to albumin ratio is an inflammatory indicator which can make a determination of disease severity.

Treatment groups

7,000 Participants

are divided into 4 treatment groups

Group A: Non-MAFLD group0 interventions

Group B: MAFLD group1 intervention

Group C: Non-fibrosis group0 interventions

Group D: Fibrosis group1 intervention

Trial outcomes

Primary outcomes

Controlled attenuation parameter

Controlled attenuation parameter is an ultrasound indicator measured by FibroScan to evaluate the degree of liver steatosis

Time frame

at baseline

Secondary outcomes

Liver stiffness measurement

Liver stiffness measurement is an ultrasound indicator measured by FibroScan to evaluate the degree of liver stiffness

Time frame

at baseline

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chongqing Medical University

Lead sponsor

Source ClinicalTrials.gov

Apply now